CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 51 enrolled
Drug / intervention
V117957 +1 moredrug
Likely dose
V117957 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06024642
NCT06024642Phase 1Completed
CompareCT.gov

Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Overactive Bladder Syndrome

Imbrium Therapeutics·interventional·Posted Sep 6, 2023·Updated Jun 26, 2025

In Brief

A Phase 1 clinical trial evaluating V117957 and Placebo for Overactive Bladder Syndrome. Completed, enrolled 51 participants across 12 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder Syndrome
CountriesUnited States
CollaboratorsPurdue Pharma LP

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedSep 6, 2023
Enrollment StartJun 30, 2022
Primary CompletionMay 21, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 2.8 years ago

Interventions

V117957drug

V117957 1 mg - 1 tablet taken orally at bedtime.

Placebodrug

Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.